PharmaCyte Biotech (PMCB) Earnings Analysis

PharmaCyte Biotech (PMCB) has no confirmed upcoming earnings date. Last quarter (2026-03-17) it beat with EPS 0.13 USD vs -0.06 USD est (+316.7%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E -0.59.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does PMCB next report earnings?

No confirmed upcoming earnings date is currently scheduled for PMCB. This page updates as the calendar is published.

PMCB earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-170.13 USD-0.06 USD+316.7%Beat
2025-12-18-0.32 USDn/an/an/a
2025-09-15-0.09 USDn/an/an/a
2025-08-111.73 USDn/an/an/a
2025-03-17-0.1 USDn/an/an/a
2024-12-13-0.29 USDn/an/an/a
2024-09-160.14 USDn/an/an/a

Beat rate: 1/1 (100%) over reported quarters with consensus data.

PMCB valuation and analyst view

Trailing P/E-0.59
Trailing EPS-0.35428 USD
Price / book0.14
Dividend yield0.00%
Market cap0.00B
Analyst consensusHold (0 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is PharmaCyte Biotech (PMCB)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for PMCB. This page updates as the calendar is published.

Did PMCB beat earnings last quarter?

In its 2026-03-17 report, PMCB posted EPS of 0.13 USD versus a -0.06 USD estimate — a beat of 316.7%.

What is PMCB's earnings track record?

Over the last 1 reported quarters with consensus data, PMCB beat estimates 1 times (100%).

What is PMCB's current P/E ratio and EPS?

PMCB trades at a trailing P/E of -0.59 on trailing EPS of -0.3542793459751875 USD.

What do analysts rate PMCB?

Analyst consensus is "Hold" across 1 ratings (0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell).